Nakata K, Nishimura K, Takada T, Ikuse T, Yamauchi H, Iso T
J Cardiovasc Pharmacol. 1987 Mar;9(3):305-10. doi: 10.1097/00005344-198703000-00007.
Effects of an angiotensin-converting enzyme (ACE) inhibitor, SA446, on the renin-angiotensin system, particularly on tissue ACE activity, were studied in Wistar-Kyoto normotensive rats (WKY), spontaneously hypertensive rats (SHR), and two-kidney, one-clip renal hypertensive rats (RHR) by repeated oral administration for 7 days. SA446 (45 mg/kg/day p.o.) inhibited ACE activity in the lung, brain, kidney, heart, and whole blood throughout the administration period in WKY, but showed a slight hypotensive action and no inhibition of aorta ACE activity. On the other hand, SA446 had an apparent hypotensive action at the same dose in SHR and inhibited ACE activity significantly in the aorta as well as the kidney and whole blood during the administration period. Furthermore, enzyme activity in the aorta, kidney, heart, and whole blood was also inhibited at a hypotensive dose of SA446 (10 mg/kg/day p.o.) in RHR. The inhibition in whole blood and kidney was almost complete, and the inhibition in the aorta was greater on day 7 than on day 1. The maximum decrease of blood pressure was correlated with the maximum inhibition in aorta ACE activity, but not in brain, lung, or heart ACE activity. In addition, a good positive correlation was observed between the basal blood pressure and the basal aorta ACE activity in WKY, SHR, and RHR, although there was no correlation in the brain, lung, kidney, heart, or whole blood. These results suggest that the antihypertensive action of SA446 by repeated administration may be due to inhibition of arterial ACE activity in addition to inhibition of plasma and kidney ACE activity.(ABSTRACT TRUNCATED AT 250 WORDS)
通过对Wistar-Kyoto正常血压大鼠(WKY)、自发性高血压大鼠(SHR)和两肾一夹肾性高血压大鼠(RHR)连续7天重复口服给药,研究了血管紧张素转换酶(ACE)抑制剂SA446对肾素-血管紧张素系统,特别是对组织ACE活性的影响。SA446(45毫克/千克/天,口服)在给药期间抑制了WKY的肺、脑、肾、心脏和全血中的ACE活性,但显示出轻微的降压作用,且未抑制主动脉ACE活性。另一方面,SA446在相同剂量下对SHR有明显的降压作用,并且在给药期间显著抑制了主动脉以及肾脏和全血中的ACE活性。此外,在RHR中,SA446的降压剂量(10毫克/千克/天,口服)也抑制了主动脉、肾脏、心脏和全血中的酶活性。全血和肾脏中的抑制几乎是完全的,主动脉中的抑制在第7天比第1天更大。血压的最大降幅与主动脉ACE活性的最大抑制相关,但与脑、肺或心脏ACE活性无关。此外,在WKY、SHR和RHR中,基础血压与基础主动脉ACE活性之间观察到良好的正相关,尽管在脑、肺